Trial Profile
A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AC-170 Ophthalmic Solution
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Sep 2018
Price :
$35
*
At a glance
- Drugs Cetirizine (Primary)
- Indications Allergic conjunctivitis
- Focus Adverse reactions; Registrational
- Sponsors NicOx
- 06 Sep 2016 Status changed from recruiting to completed.
- 04 May 2016 New trial record